oliceridine (Olinvyk)

Introduction

FDA-approved August 2020

Indications

• moderate to severe acute pain in adults
  • indicated for short-term IV use in hospitals or outpatient procedures

Contraindications

• not for at-home use

Dosage

• intravenous administration
• maximum recommended daily dose 27 mg.

Pharmacokinetics

• inactive metabolite

Adverse effects

• less risk of respiratory depression & gastrointestinal dysfunction than morphine
• QT prolongation at higher doses

* boxed warning:

• addiction, abuse & misuse
  • life-threatening respiratory depression
  • neonatal opioid withdrawal syndrome
  • risks from concomitant use with benzodiazepines or other CNS depressants

• drug adverse effects of opiates
• drug adverse effects of psychotropic agents
• drug adverse effects of sedatives

Drug interactions

• benzodiazepines

• drug interaction(s) of benzodiazepine with opiates
• drug interaction(s) of antidepressant with opiates
• drug interaction(s) of Z-drugs with opiates
• drug interaction(s) of alcoholic beverage with opiates
• drug interaction(s) of pregabalin with opiates
• drug interaction(s) of gabapentin with opiates

Mechanism of action

• G protein-selective agonist that targets the mu opioid receptor

More general terms

• opioid receptor agonist (narcotic)